Sanofi (SNY)
Pre-Market:
| Previous Close | 46.30 |
| Open | 46.14 |
| Bid | 47.02 x 200 |
| Ask | 47.07 x 100 |
| Day's Range | 46.12 - 47.16 |
| 52 Week Range | 42.63 - 57.82 |
| Volume | |
| Avg. Volume | 1,956,530 |
| Market Cap | 117.708B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 20.59 |
| EPS (TTM) | 2.29 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.04 (4.32%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 59.12 |
GlobeNewswirePress Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele
ReutersSanofi to overhaul US operations of vaccines, cut jobs
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.
- GlobeNewswire
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS
